PMID- 28184970
OWN - NLM
STAT- MEDLINE
DCOM- 20170925
LR  - 20240426
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 66
IP  - 5
DP  - 2017 May
TI  - Differences in the frequencies of HLA-class I and II alleles between German 
      patients with renal cell carcinoma and healthy controls.
PG  - 565-571
LID - 10.1007/s00262-017-1957-3 [doi]
AB  - The human leukocyte antigen (HLA) system is a major part of the human immune 
      system and has an impact on tumor initiation, tumor progression, and 
      immunosurveillance. Renal cell carcinoma tumors are considered to be immunogenic. 
      Therefore, we studied the allele frequencies of four gene loci (HLA-A, -B, -C, 
      and HLA-DR) in a cohort of German renal cell carcinoma (RCC) patients and in 
      healthy controls. HLA-A-C were determined using serological methods, whereas 
      HLA-C12, C14, C16, C18, and HLA-DR were characterized through the use of standard 
      molecular biological methods. The occurrence of the HLA-C*12 allele was 
      significantly increased in German RCC patients compared with healthy controls 
      (P < 0.005; Fisher's exact test), whereas the occurrence of the HLA-DRB1*04 
      allele was significantly reduced in RCC patients compared with healthy controls 
      (P < 0.05; Fisher's exact test). However, the presence of allele HLA-C*12 was not 
      significantly associated with 10 year overall survival. We suggest that the 
      frequency of HLA alleles can affect development of RCC and could add knowledge as 
      predictive marker for future immunotherapies.
FAU - Goebel, Steffen
AU  - Goebel S
AD  - Institute of Transfusion Medicine, Martin-Luther-University Halle-Wittenberg, 
      Halle, Germany.
FAU - Kehlen, Astrid
AU  - Kehlen A
AD  - Institute of Medical Microbiology, Martin-Luther-University Halle-Wittenberg, 
      Halle, Germany.
FAU - Bluemke, Karen
AU  - Bluemke K
AD  - Institute of Legal Medicine, Martin-Luther-University Halle-Wittenberg, Halle, 
      Germany.
FAU - Altermann, Wolfgang
AU  - Altermann W
AD  - HLA-Laboratory, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
FAU - Schlaf, Gerald
AU  - Schlaf G
AD  - HLA-Laboratory, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
FAU - Fischer, Kersten
AU  - Fischer K
AD  - Clinic of Urology, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
FAU - Fornara, Paolo
AU  - Fornara P
AD  - Clinic of Urology, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
FAU - Wullich, Bernd
AU  - Wullich B
AD  - Division Molecular Urology, Department of Urology and Pediatric Urology, 
      University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nurnberg, 
      Hartmannstr. 14, 91054, Erlangen, Germany.
FAU - Wach, Sven
AU  - Wach S
AD  - Division Molecular Urology, Department of Urology and Pediatric Urology, 
      University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nurnberg, 
      Hartmannstr. 14, 91054, Erlangen, Germany.
FAU - Taubert, Helge
AU  - Taubert H
AD  - Division Molecular Urology, Department of Urology and Pediatric Urology, 
      University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nurnberg, 
      Hartmannstr. 14, 91054, Erlangen, Germany. helge.taubert@uk-erlangen.de.
LA  - eng
PT  - Journal Article
DEP - 20170209
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-C Antigens)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Renal Cell/*genetics/*immunology
MH  - Case-Control Studies
MH  - Female
MH  - Gene Frequency/*immunology
MH  - Germany
MH  - HLA-A Antigens/genetics/immunology
MH  - HLA-B Antigens/genetics/immunology
MH  - HLA-C Antigens/genetics/immunology
MH  - HLA-DR Antigens/genetics/immunology
MH  - Histocompatibility Antigens Class I/*genetics/immunology
MH  - Histocompatibility Antigens Class II/*genetics/immunology
MH  - Humans
MH  - Kidney Neoplasms/*genetics/*immunology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
PMC - PMC11029131
OTO - NOTNLM
OT  - Allele frequency
OT  - HLA system
OT  - Prognosis
OT  - Renal cell carcinoma
COIS- The authors declare that they have no conflict of interest.
EDAT- 2017/02/12 06:00
MHDA- 2017/09/26 06:00
PMCR- 2017/02/09
CRDT- 2017/02/11 06:00
PHST- 2016/03/07 00:00 [received]
PHST- 2017/01/18 00:00 [accepted]
PHST- 2017/02/12 06:00 [pubmed]
PHST- 2017/09/26 06:00 [medline]
PHST- 2017/02/11 06:00 [entrez]
PHST- 2017/02/09 00:00 [pmc-release]
AID - 10.1007/s00262-017-1957-3 [pii]
AID - 1957 [pii]
AID - 10.1007/s00262-017-1957-3 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2017 May;66(5):565-571. doi: 
      10.1007/s00262-017-1957-3. Epub 2017 Feb 9.